风险分层的局限期霍奇金淋巴瘤患者接受ABVD方案后BV巩固治疗
这项2期多中心研究纳入41例非巨块型局限期霍奇金淋巴瘤患者,先接受2至6周期ABVD方案,再接受6周期维布妥昔单抗(BV)巩固治疗。可评估患者中95%(37/39;95%CI 83%-99%)达到PET阴性,意向治疗人群估计3年无进展生存率为92%、总生存率为97%,中位随访47个月。
要点
- 非巨块型局限期霍奇金淋巴瘤患者接受ABVD后BV巩固,可评估者PET阴性率达95%。
- 意向治疗人群估计3年无进展生存率92%、总生存率97%,中位随访47个月。
- BV巩固后PET阴性的37例患者均未接受放疗并维持缓解,估计3年无进展生存率和总生存率均为100%。
核心结论
- 在局限期霍奇金淋巴瘤中,ABVD治疗后序贯BV巩固显示出令人鼓舞的临床活性。
- 早期加入BV可能减少放疗和传统化疗药物的使用,同时在风险分层的非巨块型局限期霍奇金淋巴瘤患者中取得良好的生存结局。
研究设计与样本
- 2期多中心研究,纳入41例非巨块型局限期霍奇金淋巴瘤患者。
- 患者中位年龄29岁(范围19至67岁),58%为女性,45%为不良预后疾病,98%为II期疾病。
- 基于PET的风险分层,患者接受2至6周期ABVD方案后接受6周期BV巩固治疗。
- 试验注册号为NCT01578967。
主要发现
- ABVD后BV治疗后,可评估患者中95%(37/39;95%CI 83%-99%)达到PET阴性状态。
- 意向治疗人群中,估计3年无进展生存率为92%,总生存率为97%,中位随访47个月。
- BV巩固后达到PET阴性的37例患者均有效避免了放疗并维持缓解,估计3年无进展生存率和总生存率均为100%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Approximately 90% of limited-stage Hodgkin lymphoma (HL) patients are projected to be cured with standard therapy, but many do not live their expected life span because of late treatment-related complications. New treatment paradigms are needed to reduce the use of radiation therapy (RT) as well as conventional chemotherapy drugs while improving upon current standard-of-care survival outcomes. In this phase 2 multicenter study, patients with non-bulky limited-stage HL received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by brentuximab vedotin (BV) consolidation. Forty-one patients were enrolled, and patient characteristics included median age of 29 years (range, 19 to 67 years), 58% were female, 45% had unfavorable disease, and 98% had stage II disease. Based on positron emission tomography (PET)-based risk stratification, patients received 2 to 6 cycles of ABVD followed by 6 cycles of BV. After ABVD followed by BV, 95% of evaluable patients (37 out of 39; 95% confidence interval [CI], 83%-99%) achieved PET-negative status. In the intent-to-treat patient population, the estimated 3-year progression-free survival (PFS) rate was 92%, and the overall survival (OS) rate was 97%, with a median follow-up of 47 months. All 37 patients who achieved negative PET status after BV consolidation effectively avoided RT and remain in remission with estimated 3-year PFS and OS rates of 100%. In conclusion, BV demonstrates encouraging clinical activity when it follows ABVD therapy in limited-stage HL. Early incorporation of BV may reduce the use of RT as well as conventional chemotherapy drugs while achieving favorable survival outcomes in risk-stratified patients with non-bulky limited-stage HL. This trial was registered at www.clinicaltrials.gov as #NCT01578967.
引用
- Park SI, Shea TC, Olajide O, et al. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. Blood Adv. 2020. PMID: 32516414. doi:10.1182/bloodadvances.2020001871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。